4//SEC Filing
CGI Cellerate RX, LLC 4
Accession 0000908662-20-000031
CIK 0000714256other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 4:02 PM ET
Size
15.3 KB
Accession
0000908662-20-000031
Insider Transaction Report
Form 4
CGI Cellerate RX, LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-02-07+2,273,630→ 2,273,630 total - Conversion
5% Convertible Promissory Note
2020-02-07→ 0 totalExercise: $9.00From: 2019-08-28Exp: 2021-03-01→ Common Stock (179,101 underlying) - Conversion
Common Stock
2020-02-07$9.00/sh+179,101$1,611,909→ 2,452,731 total - Conversion
Series F Convertible Preferred Stock
2020-02-07−1,136,815→ 0 total→ Common Stock (2,273,630 underlying)
Catalyst Rochal, LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-02-07+2,273,630→ 2,273,630 total - Conversion
5% Convertible Promissory Note
2020-02-07→ 0 totalExercise: $9.00From: 2019-08-28Exp: 2021-03-01→ Common Stock (179,101 underlying) - Conversion
Common Stock
2020-02-07$9.00/sh+179,101$1,611,909→ 2,452,731 total - Conversion
Series F Convertible Preferred Stock
2020-02-07−1,136,815→ 0 total→ Common Stock (2,273,630 underlying)
Gurasich Bradley J.
10% Owner
Transactions
- Conversion
Common Stock
2020-02-07+2,273,630→ 2,273,630 total - Conversion
Series F Convertible Preferred Stock
2020-02-07−1,136,815→ 0 total→ Common Stock (2,273,630 underlying) - Conversion
Common Stock
2020-02-07$9.00/sh+179,101$1,611,909→ 2,452,731 total - Conversion
5% Convertible Promissory Note
2020-02-07→ 0 totalExercise: $9.00From: 2019-08-28Exp: 2021-03-01→ Common Stock (179,101 underlying)
Footnotes (3)
- [F1]The Series F Convertible Preferred Stock was convertible into Common Stock at any tme on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for1 in accordance with the terms of the Series F Convertible Preferred Stock.
- [F2]Reflects shares of Common Stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Gurasich is a manager of Catalyst Rochal, LLC. By virture of these relationships, Mr. Gurasich, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the Common Stock. Mr. Gurasich and Catalyst Rochal, LLC disclaim beneficial ownership of any Common Stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.
- [F3]The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.
Documents
Issuer
Sanara MedTech Inc.
CIK 0000714256
Entity typeother
IncorporatedTX
Related Parties
1- filerCIK 0001766396
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 4:02 PM ET
- Size
- 15.3 KB